Listings in the U.S. and Europe
QIAGEN’s common shares have been registered and traded in the United States since 1996, listing on the New York Stock Exchange effective January 10, 2018, after trading on NASDAQ markets since the initial public offering (IPO). The shares have traded in Germany on the Frankfurt Stock Exchange since 1997, and the Prime Standard segment since its launch in 2003. Dual listing on NYSE and the Frankfurt exchange offers advantages for QIAGEN, our shareholders and employees since global presence increases the potential market opportunity and enhances liquidity. Unlike American Depositary Receipts (ADRs), QIAGEN shares provide equal corporate rights for all shareholders and can be traded on either exchange, in U.S. dollars or euros.
|NYSE (effective January 10, 2018) / NASDAQ (until January 9, 2018)||2019||2018||2017|
|Year-end price|| $33.80
|Average daily trading volume (in million shares)||1.56||0.99||0.95|
|Frankfurt Stock Exchange (XETRA)||2019||2018||2017|
|Average daily trading volume (in million shares)||0.60||0.53||0.44|
QIAGEN is a constituent in various European, U.S. and global stock indices, some of which serve as benchmarks or investment universes for mutual funds and exchange traded funds. QIAGEN ranks as one of the leading components by market capitalization in Germany’s TecDAX index, which includes the 30 largest German technology companies not in the benchmark DAX index. Effective September 24, 2018, QIAGEN is also a member of MDAX, which includes the 60 largest comapnies in Germany after the 30 largest companies included in the DAX. QIAGEN also is a member of the Russell 3000 index, which measures performance of the 3,000 largest U.S. companies, and the Russell 1000, a subset with the largest 1,000 U.S. securities. QIAGEN shares also are included in other stock market indexes such as the MSCI Europe, EMU and EAFE indexes.
|Key share data||2019||2018||2017|
|Total equity (in $ thousands)||2,536,591||2,634,970||2,540,996|
|Issued shares (in thousands)||230,829||230,829||230,829|
|Outstanding shares at December 31 (in thousands)||227,752||225,509||226,557|
|Weighted-average number of common shares outstanding - basic (in thousands)||226,777||226,640||228,074|
|Weighted-average number of common shares outstanding - diluted (in thousands)||226,777||233,456||233,009|
|Year-end market capitalization (in $ million)||7,698||7,769||7,002|
|Year-end market capitalization (in € million)||6,937||6,693||5,928|